Biomea Fusion (BMEA) Receivables - Accured (2024 - 2025)

Biomea Fusion (BMEA) posted Receivables - Accured of $22000.0 for Q3 2025, little changed sequentially from $22000.0 in Q2 2025.

Biomea Fusion (BMEA) Receivables - Accured (2024 - 2025) Analysis & Trends

Biomea Fusion has reported Receivables - Accured for 2 years, with the latest figure at $22000.0 in Q3 2025.

Quarterly Receivables - Accured changed N/A year-over-year to $22000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $22000.0 (changed N/A YoY) and the FY2024 annual result came in at $24000.0, changed N/A from the prior year.
Receivables - Accured was little changed at $22000.0 in Q3 2025 per BMEA's latest filing, from $22000.0 in the prior quarter.
Over five years, Receivables - Accured peaked at $24000.0 in Q4 2024 and troughed at $22000.0 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables - Accured (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Biomea Fusion	97.69 Mn	97.69 Mn	-	-

Download Data